The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the OAsIs trial (NCT02558816), a multicenter, non-randomized, phase I study designed to assess the safety, tolerability, and efficacy of ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma (MCL). Prof. Rule reveals combination therapies may be relevant for the future, in order to improve outcomes whilst moving away from chemotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
